NATCO PHARMA Latest Share Price (NATCOPHARM)
TODAY IN ONE LINE
NATCOPHARM fell 1.8% on light volume, in line with Nifty's -1.6% move, hovering dangerously near its 52-week low.
With a market cap of ₹14,257.15 Cr., it trades at a P/E of 12.46. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
NATCO PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 38.9%
- ●Reasonable ValuationTrading at a moderate P/E of 11.7x
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.08x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 34.1% YoY
- ●Sales ContractionQuarterly sales dropped 18.9% YoY
- ●Rising Receivables vs SalesReceivables grew 10.8% outpacing sales growth of 10.8%
Latest NATCO PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
NATCO PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for NATCO PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
NATCO PHARMA trades at a P/E of 12.46× and P/B of 1.55×, against the Healthcare sector median P/E of 45.09×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
NATCO PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for NATCO PHARMA — derived from the latest tape, not yesterday's close.
NATCO PHARMA last traded at ₹795.4 with an intraday range of ₹792.1–₹819 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹795.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 866.03 | +70.63 | +8.88% |
| R3 | 839.13 | +43.73 | +5.50% |
| R2 | 829.07 | +33.67 | +4.23% |
| R1 | 812.23 | +16.83 | +2.12% |
| PIVOT | 802.17 | 6.77 | 0.85% |
| CURRENT | 795.40 | — | — |
| S1 | 785.33 | -10.07 | -1.27% |
| S2 | 775.27 | -20.13 | -2.53% |
| S3 | 758.43 | -36.97 | -4.65% |
| S4 | 731.53 | -63.87 | -8.03% |
NATCOPHARM is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹806.6–₹819
Trading Below opening range, showing Bearishness
NATCO PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for NATCO PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
NATCO PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹14,257.15 Cr. and reported EPS of ₹4.17.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 4,430 | 4,078 ▼ 7.9% |
| Sales Growth YoY %Derived | 10.77% | -7.93% |
| Other Income | 355 | 298 ▼ 16.1% |
| Total Income | 4,784 | 4,376 ▼ 8.5% |
| 690 | 691 ▲ 0.1% | |
| Gross ProfitDerived | 3,740 | 3,388 ▼ 9.4% |
| Gross Margin %Derived | 84.43% | 83.07% |
| 1,544 | 1,951 ▲ 26.4% | |
| EBITDA (Operating Profit)Derived | 2,196 | 1,437 ▼ 34.6% |
| OPM %Derived | 49.58% | 35.22% |
| 259 | 243 ▼ 6.1% | |
| Profit Before Tax (PBT) | 2,291 | 1,491 ▼ 34.9% |
| 408 | 119 ▼ 70.9% | |
| Effective Tax %Derived | 17.81% | 7.98% |
| Total Profit for Period | 1,883 | 1,419 ▼ 24.7% |
| Less: Non-controlling Interests | -2 | — ▲ 100.0% |
| Net Profit (Owner's PAT)Derived | 1,885 | 1,419 ▼ 24.8% |
| Net Profit Margin %Derived | 42.56% | 34.78% |
| PAT Growth YoY %Derived | 35.81% | -24.76% |
| Earnings Per Share (EPS ₹) | 105.26 | 79.20 ▼ 24.8% |
| Diluted Shares Outstanding (Cr) | 18 | 18 ▲ 0.0% |
| Share of Profit from Associates/JVs | — | 47 |
| Other Comprehensive Income (Net of Tax) | -24 | 287 ▲ 1297.5% |
| Total Expenses (incl. D&A & Interest) | 2,493 | 2,885 ▲ 15.7% |
| Material Cost % of RevenueDerived | 12.11% | 14.55% |
| Employee Cost % of RevenueDerived | 13.42% | 16.85% |
| Other Cost % of RevenueDerived | 21.43% | 31.00% |
| Interest Coverage (x)Derived | 82.04x | 33.51x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,202 | 2,095 ▼ 4.9% | 1,915 ▼ 8.6% | 2,052 ▲ 7.2% | 1,945 ▼ 5.2% | 2,707 ▲ 39.2% | 3,999 ▲ 47.7% | 4,430 ▲ 10.8% | 4,078 ▼ 7.9% | |
| Sales Growth YoY %Derived | — | -4.88% | -8.57% | 7.16% | -5.23% | 39.20% | 47.72% | 10.77% | -7.93% | |
| Other Income | 40 | 130 ▲ 222.3% | 107 ▼ 17.5% | 104 ▼ 3.5% | 99 ▼ 4.4% | 105 ▲ 5.7% | 128 ▲ 22.5% | 355 ▲ 176.7% | 298 ▼ 16.1% | |
| Total Income | 2,242 | 2,225 ▼ 0.8% | 2,022 ▼ 9.1% | 2,156 ▲ 6.6% | 2,044 ▼ 5.2% | 2,812 ▲ 37.6% | 4,127 ▲ 46.8% | 4,784 ▲ 15.9% | 4,376 ▼ 8.5% | |
411 | 354 ▼ 13.8% | 382 ▲ 7.7% | 511 ▲ 34.0% | 561 ▲ 9.7% | 627 ▲ 11.8% | 717 ▲ 14.2% | 690 ▼ 3.7% | 691 ▲ 0.1% | ||
| Gross ProfitDerived | 1,791 | 1,740 ▼ 2.8% | 1,533 ▼ 11.9% | 1,541 ▲ 0.5% | 1,384 ▼ 10.2% | 2,080 ▲ 50.3% | 3,282 ▲ 57.8% | 3,740 ▲ 13.9% | 3,388 ▼ 9.4% | |
| Gross Margin %Derived | 81.33% | 83.09% | 80.07% | 75.08% | 71.16% | 76.83% | 82.08% | 84.43% | 83.07% | |
863 | 946 ▲ 9.6% | 951 ▲ 0.6% | 935 ▼ 1.7% | 1,120 ▲ 19.9% | 1,144 ▲ 2.1% | 1,531 ▲ 33.8% | 1,544 ▲ 0.8% | 1,951 ▲ 26.4% | ||
| EBITDA (Operating Profit)Derived | 928 | 795 ▼ 14.4% | 583 ▼ 26.7% | 606 ▲ 4.1% | 264 ▼ 56.5% | 936 ▲ 255.1% | 1,751 ▲ 87.2% | 2,196 ▲ 25.4% | 1,437 ▼ 34.6% | |
| OPM %Derived | 42.16% | 37.95% | 30.42% | 29.54% | 13.55% | 34.56% | 43.80% | 49.58% | 35.22% | |
82 | 100 ▲ 22.9% | 121 ▲ 20.9% | 130 ▲ 7.3% | 160 ▲ 23.1% | 178 ▲ 11.2% | 206 ▲ 15.5% | 259 ▲ 25.8% | 243 ▼ 6.1% | ||
| Profit Before Tax (PBT) | 887 | 825 ▼ 7.0% | 569 ▼ 31.0% | 580 ▲ 1.9% | 202 ▼ 65.1% | 862 ▲ 326.3% | 1,674 ▲ 94.2% | 2,291 ▲ 36.9% | 1,491 ▼ 34.9% | |
192 | 182 ▼ 5.1% | 111 ▼ 39.3% | 137 ▲ 24.1% | 32 ▼ 76.5% | 147 ▲ 355.3% | 285 ▲ 94.5% | 408 ▲ 43.1% | 119 ▼ 70.9% | ||
| Effective Tax %Derived | 21.64% | 22.11% | 19.45% | 23.67% | 15.92% | 17.01% | 17.04% | 17.81% | 7.98% | |
| Total Profit for Period | 695 | 642 ▼ 7.6% | 458 ▼ 28.7% | 442 ▼ 3.4% | 170 ▼ 61.6% | 715 ▲ 320.8% | 1,388 ▲ 94.1% | 1,883 ▲ 35.7% | 1,419 ▼ 24.7% | |
| Less: Non-controlling Interests | -1 | -2 ▼ 100.0% | -3 ▼ 35.0% | 2 ▲ 155.6% | — ▼ 100.0% | — | — | -2 | — ▲ 100.0% | |
| Net Profit (Owner's PAT)Derived | 696 | 644 ▼ 7.4% | 461 ▼ 28.5% | 441 ▼ 4.3% | 170 ▼ 61.4% | 715 ▲ 320.8% | 1,388 ▲ 94.1% | 1,885 ▲ 35.8% | 1,419 ▼ 24.8% | |
| Net Profit Margin %Derived | 31.62% | 30.77% | 24.06% | 21.49% | 8.74% | 26.42% | 34.72% | 42.56% | 34.78% | |
| PAT Growth YoY %Derived | — | -7.44% | -28.49% | -4.32% | -61.44% | 320.76% | 94.09% | 35.81% | -24.76% | |
| Earnings Per Share (EPS ₹) | 37.74 | 35.24 ▼ 6.6% | 25.31 ▼ 28.2% | 24.18 ▼ 4.5% | 9.31 ▼ 61.5% | 39.20 ▲ 321.1% | 77.51 ▲ 97.7% | 105.26 ▲ 35.8% | 79.20 ▼ 24.8% | |
| Diluted Shares Outstanding (Cr) | 18 | 18 ▼ 0.9% | 18 ▼ 0.4% | 18 ▲ 0.1% | 18 ▲ 0.1% | 18 ▼ 0.0% | 18 ▼ 1.8% | 18 ▲ 0.0% | 18 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | — | — | — | 47 | |
| Other Comprehensive Income (Net of Tax) | -5 | -8 ▼ 46.2% | -15 ▼ 90.8% | 9 ▲ 160.0% | 50 ▲ 471.3% | 3 ▼ 94.6% | 15 ▲ 451.9% | -24 ▼ 261.1% | 287 ▲ 1297.5% | |
| Total Expenses (incl. D&A & Interest) | 1,355 | 1,400 ▲ 3.3% | 1,454 ▲ 3.8% | 1,576 ▲ 8.4% | 1,842 ▲ 16.8% | 1,950 ▲ 5.9% | 2,453 ▲ 25.8% | 2,493 ▲ 1.6% | 2,885 ▲ 15.7% | |
| Material Cost % of RevenueDerived | 17.73% | 15.90% | 17.18% | 18.17% | 26.70% | 17.56% | 13.07% | 12.11% | 14.55% | |
| Employee Cost % of RevenueDerived | 14.79% | 16.99% | 19.58% | 20.22% | 22.87% | 17.98% | 13.13% | 13.42% | 16.85% | |
| Other Cost % of RevenueDerived | 24.38% | 28.15% | 30.07% | 25.32% | 34.74% | 24.29% | 25.15% | 21.43% | 31.00% | |
| Interest Coverage (x)Derived | 55.99x | 36.98x | 22.46x | 36.79x | 6.83x | 53.23x | 81.49x | 82.04x | 33.51x |
NATCO PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at NATCO PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
NATCO PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for NATCO PHARMA.
Our AI distills the core fundamental drivers supporting NATCO PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
NATCO PHARMA's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 16 (~0.4× the sector multiple of 45.1) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 10% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.28%.
NATCO PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — NATCO PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
NATCO PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for NATCO PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
NATCO PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for NATCO PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in NATCO PHARMA stood at 53.9% of traded volume, against a 20-day average of 52.9%.
NATCO PHARMA announcements: results, concalls, ratings, M&A.
Filings NATCO PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
NATCO PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 167 documents below.
Trading Window
Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Shareholders meeting
Natco Pharma Limited has submitted the Exchange a copy Srutinizers report of 43rd Annual General Meeting held on September 30, 2026. Further, the…
Shareholders meeting
Natco Pharma Limited has informed the Exchange regarding Proceedings of 43rd Annual General Meeting held on September 30, 2026
Committee Meeting Updates
Natco Pharma Limited has informed the Exchange regarding Outcome of Fund Raising Committee Meeting approving the Letter of Offer for Rights Issue
Press Release
Natco Pharma Limited has informed the Exchange regarding a press release dated September 28, 2026, titled "Press Release under SEBI (LODR)…
Investor decks & rating reports.
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
NATCO PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue NATCO PHARMA has declared, sequenced by announce and record date.
NATCO PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
NATCO PHARMA insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in NATCO PHARMA as reported to SEBI — buying and selling signals from the people who know the business best.
NATCO PHARMA insider activity below tracks 15 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| SATYA VANI NANNAPANENI | Insider | 09 Mar 2026 | buy | +45.0 K | ₹4.51 Cr. | ₹1,001.33 |
| SANJAY NANNAPANENI | Insider | 09 Mar 2026 | buy | +70.0 K | ₹7.12 Cr. | ₹1,017.31 |
| SATYA VANI NANNAPANENI | Insider | 09 Mar 2026 | buy | +45.0 K | ₹4.51 Cr. | ₹1,001.33 |
| SANJAY NANNAPANENI | Insider | 09 Mar 2026 | buy | +70.0 K | ₹7.12 Cr. | ₹1,017.31 |
| SATYA VANI NANNAPANENI | Insider | 09 Mar 2026 | buy | +45.0 K | ₹4.51 Cr. | ₹1,001.33 |
| SANJAY NANNAPANENI | Insider | 09 Mar 2026 | buy | +70.0 K | ₹7.12 Cr. | ₹1,017.31 |
| PRAGNYA RAO DONTHINENI | Insider | 10 Jun 2025 | buy | +100 | ₹86,500 | ₹865.00 |
| SANJAY NANNAPANENI | Insider | 26 Mar 2025 | buy | +2.87 L | — | — |
| VENKATA SATYA SWATHI KANTAMANI | Insider | 20 Mar 2025 | sell | −50.0 K | — | — |
| RAJEEV NANNAPANENI | Insider | 20 Mar 2025 | sell | −50.0 K | — | — |
About NATCO PHARMA: business, sector, key facts.
What NATCO PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
NATCO PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NATCOPHARM, BSE: 524816.
NATCO Pharma Limited is a global pharmaceutical company with a diverse business model encompassing the development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates. Their operations span India, the United States, and other international markets, showcasing a significant reach in the pharmaceutical industry.
A core component of NATCO's business is the production and sale of finished dosage formulations targeting a wide range of therapeutic areas. These formulations are particularly strong in oncology, addressing various cancers including those affecting the blood, liver, kidney, lung, brain, breast, and ovary. Beyond oncology, they also offer products for cardiology and diabetology, specifically targeting conditions like hypertension, stable angina, and congestive heart failure (CHF).
In addition to finished formulations, NATCO Pharma is a significant player in the API market. They manufacture APIs across several therapeutic categories, mirroring the focus of their finished dosage formulations. These categories include oncology, central nervous system treatments, pain management solutions, and cardiovascular care medications. This vertical integration, controlling both API and formulation production, gives them a strategic advantage in the market.
Further diversifying their portfolio, NATCO Pharma provides specialized products in orthopedics, notably bisphosphonates in both oral and injectable forms. They also cater to gastroenterology needs with novel drugs targeting chronic hepatitis B and C. Furthermore, the company offers contract manufacturing services, leveraging their manufacturing expertise to provide services for other pharmaceutical entities.
Beyond human pharmaceuticals, NATCO Pharma extends its reach into the agrochemical sector. They offer a range of solutions for biological pest management, providing tools to control insects, diseases, and weeds across various crops. This expansion into agrochemicals diversifies their revenue streams and demonstrates their adaptability within the broader chemical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week low (reversal watch)Screener
- Reversal Hunter strategy playbookStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about NATCO PHARMA (NATCOPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of NATCO PHARMA (NATCOPHARM)?
The current share price of NATCO PHARMA (NATCOPHARM) is ₹795.40. Today, the stock has declined by ₹14.70 (1.81%), trading in a range of ₹792.10 to ₹819.00. The stock opened at ₹812.95 with a trading volume of 3,12,124 shares.
02Is NATCO PHARMA stock a good investment for long-term?
NATCO PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹14,257.15 Cr., P/E ratio of 12.46, ROE of 14.98%, and ROCE of 14.19%. The dividend yield stands at 0.55%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of NATCO PHARMA stock?
The 52-week high price of NATCO PHARMA (NATCOPHARM) is ₹1,226.80, while the 52-week low is ₹792.05. Currently trading at ₹795.40, the stock is 0.42% above its 52-week low and 35.16% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy NATCO PHARMA stock at the current price?
Whether to buy NATCO PHARMA stock at ₹795.40 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.46 and P/B ratio of 1.55. Today's performance shows a loss of 1.81%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of NATCO PHARMA and when is the next dividend?
NATCO PHARMA offers a dividend yield of 0.55%, which means for every ₹100 invested at the current price of ₹795.40, you can expect to receive approximately ₹0.55 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of NATCO PHARMA?
NATCO PHARMA's key financial metrics include: P/E Ratio: 12.46, P/B Ratio: 1.55, ROE: 14.98%, ROCE: 14.19%, Dividend Yield: 0.55%, EPS: ₹4.17, Book Value: ₹514.83, and Debt-to-Equity: 0.08. The company's market cap stands at ₹14,257.15 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is NATCO PHARMA stock performing today in the market?
NATCO PHARMA stock opened at ₹812.95 and is currently trading at ₹795.40, showing a decline of ₹14.70 (1.81%). The intraday high is ₹819.00 and low is ₹792.10. The trading volume stands at 3,12,124 shares, indicating moderate market participation today.
08What is the P/E ratio of NATCO PHARMA and what does it indicate?
NATCO PHARMA has a Price-to-Earnings (P/E) ratio of 12.46, which means investors are willing to pay 12.46 for every ₹1 of earnings. With an EPS of ₹4.17, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about NATCO PHARMA (NATCOPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.